erwork Reduction Act of 1995, no persons are required to respon-Application Numbe **TRANSMITTAL** Filing Date

Examiner Name

Attorney Docket Number

FORM

(to be used for all correspondence after initial filing)

Kimberly Melvin

Typed or printed name

	PTO/SB/21 (09-04) Approved for use through 07/31/2006. OMB 0651-0031 Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE of information unless it displays a valid OMB control number.
Application Number	10/050,651
Filing Date	January 14, 2002
First Named Inventor	GALLAGHER, Brenden P.
Art Unit	3731

Date

December 17, 2004

BAXTER, Jessica

Tota	Number of Pages in This Submission	į	Attorney Docket Number	PA871		<i></i>		
ENCLOSURES (Check all that apply)								
Fee Transmittal Form Fee Attached Amendment/Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement Certified Copy of Priority Document(s) Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53			Drawing(s) Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence Address Terminal Disclaimer Request for Refund CD, Number of CD(s) Landscape Table on CD Remarks		Resp	After Allowance Communication to TC Appeal Communication to Board of Appeals and Interferences Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter		
	SIGNA	TURE C	OF APPLICANT, ATT	ORNEY, C	OR AGI	ENT		
Firm N	Ame Medtronic Vascular, Inc.		, · · · · · · · · · · · · · · · · · · ·					
Signature Calando								
Printed	name Catherine C. Maresh							
Date December 17, 2004			Reg. No.		35,268			
CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:								
Signature								

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to life (and by the GSP 1.6 process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ap 3 73/



CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Mail Stop AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on December 17, 2004.

Signed: _

Kimberly Melvin

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appln. No.

10/050,651

Confirmation No.:

6007

Applicant

Brendan P. Gallagher January 14, 2002

Filed TC/A.U.

3731

Examiner

Jessica R. Baxter

Docket No.

P871 US

Customer No.

26541

Title

Stent Delivery System

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

RESPONSE

Sir:

In response to the Office Communication of November 12, 2004, please amend the above-identified application as follows:

Amendments to the Specification begin on page 2 of this paper.

Amendments to the Claims are reflected in the listing of claims which begins on page three (3) of this paper.

Remarks/Arguments begin on page five (5) of this paper.